Towards Personalized Treatment of Prostate Cancer: PSMA I&T, a Promising Prostate-Specific Membrane Antigen-Targeted Theranostic Agent.
about
177Lu-Labeled Phosphoramidate-Based PSMA Inhibitors: The Effect of an Albumin Binder on Biodistribution and Therapeutic Efficacy in Prostate Tumor-Bearing Mice.Synthesis and pre-clinical evaluation of a new class of high-affinity 18F-labeled PSMA ligands for detection of prostate cancer by PET imaging.Full preclinical validation of the 123I-labeled anti-PSMA antibody fragment ScFvD2B for prostate cancer imaging.Gut Microbiota-Mediated Personalized Treatment of Hyperlipidemia Using Berberine.PSMA redirects cell survival signaling from the MAPK to the PI3K-AKT pathways to promote the progression of prostate cancer.A PSMA Ligand Labeled with Cobalt-55 for PET Imaging of Prostate Cancer.Influence of Androgen Deprivation Therapy on the Uptake of PSMA-Targeted Agents: Emerging Opportunities and Challenges.131I-labeled Anti-HER2 Camelid sdAb as a Theranostic Tool in Cancer Treatment.Reduction of 68Ga-PSMA renal uptake with mannitol infusion: preliminary results.The 68Ga/177Lu theragnostic concept in PSMA targeting of castration-resistant prostate cancer: correlation of SUVmax values and absorbed dose estimates.Preparation of 68Ga-PSMA-11 with a Synthesis Module for Micro PET-CT Imaging of PSMA Expression during Prostate Cancer Progression.Molecular Imaging in Oncology Using Positron Emission Tomography.Targeted α-therapy of prostate cancer using radiolabeled PSMA inhibitors: a game changer in nuclear medicine
P2860
Q33821017-863CB8C9-6234-4124-9E71-8BFEE345B0F9Q37662752-C918E59D-344D-4803-877F-7E9AED5B34A9Q37706857-1BE4FC8E-C39C-46ED-8AF0-310E990E77BCQ41114295-C62C6987-DD45-48B8-AAAD-78DD1BF8CB43Q41273648-15A30C3E-0408-4AE9-890B-2DCF0A6ADAF3Q47963642-37C09AB3-D582-4CF8-AD24-C1A4744E29B1Q48116656-D8097AEB-DAA7-4C11-A34C-E0E8DFDDB1FCQ49167649-81ED57F8-5B0D-4DA5-BE35-9AB584CB2181Q51828247-11ABD6C4-54C6-4ACF-8C2A-BEA9675DF504Q53578187-9EE31267-C54B-4715-AD99-B4ADD0D76F5CQ55039909-3891D670-71CB-4418-8866-6A90DB850AC8Q55182174-2AC7692A-EF96-4B1C-BE4E-7042E83AF8B5Q57107703-9BCCBACA-0D91-438F-85EA-8DCF904FC8FD
P2860
Towards Personalized Treatment of Prostate Cancer: PSMA I&T, a Promising Prostate-Specific Membrane Antigen-Targeted Theranostic Agent.
description
2016 nî lūn-bûn
@nan
2016年の論文
@ja
2016年論文
@yue
2016年論文
@zh-hant
2016年論文
@zh-hk
2016年論文
@zh-mo
2016年論文
@zh-tw
2016年论文
@wuu
2016年论文
@zh
2016年论文
@zh-cn
name
Towards Personalized Treatment ...... en-Targeted Theranostic Agent.
@en
Towards Personalized Treatment ...... en-Targeted Theranostic Agent.
@nl
type
label
Towards Personalized Treatment ...... en-Targeted Theranostic Agent.
@en
Towards Personalized Treatment ...... en-Targeted Theranostic Agent.
@nl
prefLabel
Towards Personalized Treatment ...... en-Targeted Theranostic Agent.
@en
Towards Personalized Treatment ...... en-Targeted Theranostic Agent.
@nl
P2093
P2860
P356
P1433
P1476
Towards Personalized Treatment ...... en-Targeted Theranostic Agent.
@en
P2093
Gerben M Franssen
Hans-Jürgen Wester
Janneke D M Molkenboer-Kuenen
Kristell L S Chatalic
Margret Schottelius
Marian C Clahsen-van Groningen
Marion de Jong
Mark Konijnenberg
Sandra Heskamp
Wytske M van Weerden
P2860
P304
P356
10.7150/THNO.14744
P577
2016-04-12T00:00:00Z